# US 2021/0262022 A1 · Liver protective marc variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0262022 A1
- Document ID: US20210262022A1
- Status: Published application
- Kind: A1
- Application number: 16/807,125
- Filed: 2020-03-02
- Published: 2021-08-26
- Earliest claimed: 2019-03-01
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: Sekar Kathiresan; Connor Emdin
- Web page: https://patentgrep.com/patent/US20210262022A1

## CPC

- C12Q 1/6858: Allele-specific amplification
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are MARC variants that associate with a risk of liver diseases or a symptom(s) thereof, such as cirrhosis, or protection against such liver diseases or symptom(s) thereof. Also described herein are compositions and formulations that can be capable of modulating MARC in a subject and/or treatment of a liver disease or a symptom thereof.

## Claims

### Claim 1

A method of treating or preventing a liver disease or a symptom thereof in a subject in need thereof comprising:
detecting a MARC1 risk allele, a MARC2 risk allele, or both in the subject in need thereof, wherein the presence of a MARC1 risk allele, a MARC2 risk allele, or both indicates that the subject in need thereof has an increased risk of liver disease; and
administering, to the subject in need thereof, an amount of a treatment or preventative effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both in the subject in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the liver disease or symptom thereof comprises liver cirrhosis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the liver disease or symptom thereof comprises alcoholic cirrhosis, non-alcoholic cirrhosis, a hepatitis-related cirrhosis, hepatic steatosis, alcohol-related fatty liver disease (ALD), or nonalcoholic fatty liver disease (NAFLD).

### Claim 4 (depends on 1)

The method of claim 1, wherein the MARC1 risk allele encodes a threonine at amino acid position 165 of SEQ ID NO: 1 or at a position equivalent to amino acid position 165 of SEQ ID NO: 1 and wherein the MARC2 risk allele encodes a threonine at a position in the MARC2 that is equivalent to amino acid position 165 of SEQ ID NO: 1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the treatment or preventative effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both comprises a MARC1-specific RNAi molecule, a MARC2-specific RNAi molecule, a small molecule agent, a MARC1-specific gene modifying agent, a MARC2-specific gene modifying agent, or a combination thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the MARC1- or MARC2-specific gene modifying agent is capable of modifying a polynucleotide encoding the threonine at position 165 of SEQ ID NO: 1 or equivalent position in the MARC1 or MARC2 to a polynucleotide encoding an alanine in a cell in the subject in need thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject in need thereof has an elevated amount, activity of, or both of or one or more of aminotransferase (ALT), triglyceride (TG), alkaline phosphatase (ALP), total cholesterol, low-density lipoprotein (LDL) cholesterol, or a combination thereof prior to administration.

### Claim 8 (depends on 7)

The method of claim 7, wherein administering the amount of a treatment or preventative effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both reduces the amount of, activity of, or both of aminotransferase (ALT), triglyceride (TG), alkaline phosphatase (ALP), total cholesterol, low-density lipoprotein (LDL) cholesterol, or a combination thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein administering the amount of a treatment or preventative effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both reduces the level of total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, or a combination thereof in the subject in need thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject in need thereof is
a) heterozygous for the high-risk MARC1 allele;
b) homozygous for the high-risk MARC1 allele;
c) heterozygous for the high-risk MARC2 allele;
d) heterozygous for the high-risk MARC1 allele;
e) or any permissible combination thereof.

### Claim 11

A method of reducing total cholesterol, low-density lipoprotein, or a combination thereof in a subject in need thereof, comprising:
administering, to the subject in need thereof, an amount of a treatment effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both in the subject in need thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject in need thereof has a MARC1 risk allele, a MARC2 risk allele, or both.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject in need thereof is
a) heterozygous for the high-risk MARC1 allele;
b) homozygous for the high-risk MARC1 allele;
c) heterozygous for the high-risk MARC2 allele;
d) heterozygous for the high-risk MARC1 allele;
e) or any permissible combination thereof.

### Claim 14 (depends on 11)

The method of claim 11, wherein the MARC1 risk allele encodes a threonine at amino acid position 165 of SEQ ID NO: 1 or at a position equivalent to amino acid position 165 of SEQ ID NO: 1 and wherein the MARC2 risk allele encodes a threonine at a position in the MARC2 that is equivalent to amino acid position 165 of SEQ ID NO: 1.

### Claim 15 (depends on 11)

The method of claim 11, wherein the treatment or preventative effective to reduce the amount of, activity of, or both of MARC1, MARC2, or both comprises a MARC1-specific RNAi molecule, a MARC2-specific RNAi molecule, a small molecule agent, a MARC1-specific gene modifying agent, a MARC2-specific gene modifying agent, or a combination thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the MARC1- or MARC2-specific gene modifying agent is capable of modifying a polynucleotide encoding the threonine at position 165 of SEQ ID NO: 1 or equivalent position in the MARC1 or MARC2 to a polynucleotide encoding an alanine in a cell in the subject in need thereof.

### Claim 17 (depends on 11)

The method of claim 11, wherein the subject in need thereof has an elevated amount, activity of, or both of or one or more of aminotransferase (ALT), triglyceride (TG), alkaline phosphatase (ALP), or a combination thereof prior to administration.

### Claim 18 (depends on 11)

The method of claim 11, wherein the subject in need thereof has a liver disease or a symptom thereof, wherein the liver disease is selected from the group consisting of: alcoholic cirrhosis, non-alcoholic cirrhosis, a hepatitis-related cirrhosis, hepatic steatosis, alcohol-related fatty liver disease (ALD), or nonalcoholic fatty liver disease (NAFLD).

### Claim 19

An agent effective to reduce an amount of, activity of, or both of MARC1, MARC2, or both or effective to treat a liver disease or a symptom thereof, or both, comprising:
comprises a MARC1-specific RNAi molecule, a MARC2-specific RNAi molecule, a small molecule agent, a MARC1-specific gene modifying agent, a MARC2-specific gene modifying agent, or a combination thereof,
wherein the agent is produced by a method comprising
administering an amount of a test agent to a subject; and
determining
a) the level or modulation thereof of a MARC1 in the subject;
b) the level or modulation thereof of a MARC2 in the subject;
c) the level of alanine transaminase (ALT) in the plasma of the subject;
d) the level of aspartate transaminase (AST) in the plasma of the subject;
e) the level of alkaline phosphatase (ALP) in the plasma of the subject;
f) the level of the total cholesterol in the subject;
g) the level of low-density lipoprotein (LDL) cholesterol in the subject;
h) the level of high-density lipoprotein (HDL) cholesterol in the subject;
i) the level of triglycerides in the subject; or
j) a combination thereof,
wherein the agent effective to reduce an amount of, activity of, or both of MARC1, MARC2, or both or effective to treat a liver disease or a symptom thereof, or both, is effective to
a) reduce the amount, activity, or both of the MARC1 in the subject;
b) reduce the amount, activity, or both of the MARC2 in the subject;
c) reduce the level of ALT in the plasma of the subject;
d) reduce the level of AST in the plasma of the subject;
e) reduce the level of ALP in the plasma of the subject;
f) reduce the level of total cholesterol in the subject;
g) reduce the level of LDL cholesterol in the subject;
h) reduce the level of HDL cholesterol in the subject;
i) reduce the level of triglycerides in the subject; or
j) any combination thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the MARC1- or MARC2-specific gene modifying agent is capable of modifying a polynucleotide encoding the threonine at position 165 of SEQ ID NO: 1 or equivalent position in the MARC1 or MARC2 to a polynucleotide encoding an alanine in a cell in the subject in need thereof.
